| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3192756 | Annals of Allergy, Asthma & Immunology | 2010 | 7 Pages |
Abstract
The addition of montelukast to an intranasal corticosteroid for the treatment of PAR with residual symptoms is no more effective than is placebo.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Rania MD, Marcy BSN, Robert M. MD, Fuad M. MD,